Protein tyrosine phosphatase PTPN22 +1858C/T polymorphism is associated with active vitiligo

Garcia‑Melendez,Martha  Elena; Salinas‑Santander,Mauricio; Sanchez‑Dominguez,Celia; Gonzalez‑Cardenas,Hugo; Cerda‑Flores,Ricardo  M.; Ocampo‑Candiani,Jorge; Ortiz‑López,Rocío

doi:10.3892/etm.2014.1975

Protein tyrosine phosphatase PTPN22 +1858C/T polymorphism is associated with active vitiligo

Authors:
- Martha Elena Garcia‑Melendez
- Mauricio Salinas‑Santander
- Celia Sanchez‑Dominguez
- Hugo Gonzalez‑Cardenas
- Ricardo M. Cerda‑Flores
- Jorge Ocampo‑Candiani
- Rocío Ortiz‑López
View Affiliations

Affiliations: Dermatology Service, Hospital Universitario ‘Dr. José Eleuterio González’, Monterrey, CP 64460, Nuevo León, Mexico, Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, CP 64460, Nuevo León, Mexico, Nursery School Faculty, Universidad Autónoma de Nuevo León, Monterrey, CP 64460, Nuevo León, Mexico
Published online on: September 17, 2014 https://doi.org/10.3892/etm.2014.1975
Pages: 1433-1437

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vitiligo is characterized by a skin depigmentation disorder resulting from an autoimmune response targeting melanocytes. Within the genetic factors involved in the development of the vitiligo immune response, various genes in the major histocompatibility complex (MHC) and non‑MHC loci have been considered to be risk factors. The PTPN22 gene encodes for a lymphoid protein tyrosine phosphatase, a regulator of the activation and development of T‑cells. The +1858C/T polymorphism has been associated to autoimmune disease susceptibility in different populations and could be implicated in the onset of vitiligo. To assess the possible association between the presence of PTPN22 +1858C/T and vitiligo, 187 patients with vitiligo and 223 control subjects were analyzed in the study. Genomic DNA was isolated using the salting‑out method and samples were subjected to polymerase chain reaction‑restriction fragment length polymorphism in order to detect the PTPN22 +1858C/T polymorphism. Causal associations were determined by χ2 test and their respective odds ratio (OR) was assessed in a 2x2 contingency table. The results showed an association between active vitiligo and the allele T load [P=0.0418; OR, 2.5706; 95% confidence interval (CI), 1.0040‑6.5816], and active vitiligo‑CT genotype (P=0.0389, OR, 2.6548; 95% CI, 1.0191‑6.9156). In conclusion, the present data indicates a possible association between the PTPN22 +1858C/T genotype and a significant susceptibility of developing an active form of vitiligo.

View Figures

View References

1	Sehgal V and Srivastava G: Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 73:149–156. 2007. View Article : Google Scholar : PubMed/NCBI
2	Guerra L, Dellambra E, Brescia S and Raskovic D: Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 11:451–467. 2010. View Article : Google Scholar : PubMed/NCBI
3	Steiner D, Bedin V, Brito M, Tadeu R and Steiner T: Vitiligo. An Bras Dermatol. 79:335–351. 2004. View Article : Google Scholar
4	Parsad D, Dogra S and Kanwar AJ: Quality of life in patients with vitiligo. Health Qual Life Outcomes. 1:58–63. 2003. View Article : Google Scholar : PubMed/NCBI
5	Moretti S: Vitiligo: Orphanet Encyclopedia. October. 2003, http://www.orpha.net/data/patho/GB/uk-vitiligo.pdfuri. Accessed December 13, 2013
6	Huggins RH, Janusz CA and Schwartz RA: Vitiligo: a sign of systemic disease. Indian J Dermatol Venereol Leprol. 72:68–71. 2006. View Article : Google Scholar : PubMed/NCBI
7	Jin Y, Mailloux CM, Gowan K, et al: NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 356:1216–1225. 2007. View Article : Google Scholar : PubMed/NCBI
8	van Gell N, Speeckaert M, et al: Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 28:741–746. 2014.PubMed/NCBI
9	Shajil EM, Chatterjee S, et al: Vitiligo: pathomechanisms and genetic polymorphism of susceptible genes. Indian J Exp Biol. 44:526–539. 2006.PubMed/NCBI
10	Kemp EH, Gavalast NG, et al: Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev. 6:138–142. 2007. View Article : Google Scholar : PubMed/NCBI
11	Almeida P, Borrego L, Rodríguez-López J, et al: Vitiligo. Treatment of 12 cases with topical tacrolimus. Actas Dermosifiliogr. 96:159–163. 2005.(In Spanish).
12	Xu AE, Zhang DM, Wei XD, Huang B and Lu LJ: Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol. 48:86–90. 2009.PubMed/NCBI
13	Amur S, Parekh A and Mummaneni P: Sex differences and genomics in autoimmune diseases. J Autoimmun. 38:J254–J165. 2012. View Article : Google Scholar : PubMed/NCBI
14	Cohen S, Dadi H, Shaoul E, Sharfe N and Roifman CM: Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood. 93:2013–2024. 1999.PubMed/NCBI
15	Zhebrun D, Kudryashova Y, Babenko A, et al: Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves’ disease but not with rheumatoid arthritis in Russian population. Aging (Albany NY). 3:368–373. 2011.PubMed/NCBI
16	Torres-Carrillo NM, Ruiz-Noa Y, et al: The +1858C/T PTPN22 gene polymorphism confers genetic susceptibility to rheumatoid arthritis in Mexican population from the Western Mexico. Immunol Lett. 147:41–46. 2012. View Article : Google Scholar : PubMed/NCBI
17	Cénit MC, Márquez A, Cordero-Coma M, et al: Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis. Mol Vis. 19:638–643. 2013.PubMed/NCBI
18	Chen YF and Chang JS: PTPN22 C1858T and the risk of psoriasis: a meta-analysis. Mol Biol Rep. 39:7861–7870. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bottini N, Musumeci L, Alonso A, et al: A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 36:337–338. 2004. View Article : Google Scholar : PubMed/NCBI
20	Cantón I, Akhtar S, Gavalas NG, Gawkrodger DJ, Blomhoff A, Watson PF, Weetman AP and Kemp EH: A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun. 6:584–587. 2005.PubMed/NCBI
21	Vang T, Miletic AV, Bottini N and Mustelin T: Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 40:453–461. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A and Weiss A: PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a nonautoimmune background. J Immunol. 182:4093–4106. 2009. View Article : Google Scholar : PubMed/NCBI
23	Laberge GS, Birlea SA, Fain PR and Spritz RA: The PTPN22-1858C>T (R620W) functional polymorphism is associated with generalized vitiligo in the Romanian population. Pigment Cell Melanoma Res. 21:206–208. 2008.
24	Baca V, Velázquez-Cruz R, Salas-Martínez G, Espinosa-Rosales F, Saldaña-Alvarez Y and Orozco L: Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population. Genes Immun. 7:693–695. 2006. View Article : Google Scholar : PubMed/NCBI
25	Harrison P, Pointon JJ, Farrar C, Brown MA and Wordsworth BP: Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients. Rheumatology (Oxford). 45:1009–1011. 2006. View Article : Google Scholar : PubMed/NCBI
26	Aris M: Origin of normal and malignant melanocytes. Acta Bioquím Clín Latinoam. 43:333–337. 2009.
27	Zhang XJ, Chen JJ and Liu JB: The genetic concept of vitiligo. J Dermatol Sci. 39:137–146. 2005. View Article : Google Scholar : PubMed/NCBI
28	Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P and Ruiz-Argüelles A: Immunopathogenesis of vitiligo. Autoimmun Rev. 10:762–765. 2011. View Article : Google Scholar
29	Sahni K and Parsad D: Stability in vitiligo: Is there a perfect way to predict it? J Cutan Aesthet Surg. 6:75–82. 2013. View Article : Google Scholar : PubMed/NCBI
30	Spritz RA: The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res. 20:271–278. 2007. View Article : Google Scholar : PubMed/NCBI
31	Burn GL, Svensson L, Sanchez-Blanco C, Saini M and Cope AP: Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett. 585:3689–3698. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, Meng X, Dong B, Xie G, Qiu F, Hao Z, McCulloch CA, Keystone EC, Peterson AC and Siminovitch KA: The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet. 43:902–907. 2011. View Article : Google Scholar : PubMed/NCBI
33	Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N, Sullivan-Whalen M, Gilleaudeau P, Cohen JA and Krueger JG: Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One. 6:e189072011. View Article : Google Scholar : PubMed/NCBI
34	Lins TC, Vieira RG, Grattapaglia D and Pereira RW: Allele and haplotype frequency distribution in PTPN22 gene across variable ethnic groups: Implications for genetic association studies for autoimmune diseases. Autoimmunity. 43:308–316. 2010. View Article : Google Scholar
35	Elmongy NN and Abu Khalil RE: PTPN22 gene polymorphism in Egyptian females with non-segmental vitiligo. Comp Clin Pathol. 22:961–964. 2013. View Article : Google Scholar
36	Song GG, Kim JH and Lee YH: The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis. Mol Biol Rep. 40:2985–2993. 2013. View Article : Google Scholar : PubMed/NCBI